Previous 10 | Next 10 |
2seventy bio press release (NASDAQ:TSVT): Q4 GAAP EPS of -$2.55 beats by $0.80. Revenue of $16.03M (+61.8% Y/Y) beats by $5.64M. For further details see: 2seventy bio GAAP EPS of -$2.55 beats by $0.80, revenue of $16.03M beats by $5.64M
Closed $170M private placement with leading healthcare investors ABECMA generated $158M U.S. commercial revenue in 2021; tracking toward upper end of $250-300M U.S. revenue guidance for 2022 Internal cost reduction measures reduce net cash spend guidance to $190-220M f...
2seventy bio (NASDAQ:TSVT) agreed to sell ~13.9M shares to a select group of institutional and accredited investors in a private placement. On financing closure, the company will receive gross proceeds of ~$170M based on $12.2/share (Mar.15 closing price). The financing is expected ...
Proceeds to support 2seventy bio’s pipeline of novel cell therapy programs Financing, combined with reduced net cash spend and ABECMA commercial progress, supports extension of cash runway into 2025 2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-onco...
PTAB turned the CRISPR industry upside down, with sleepy biotechs becoming market favorites overnight and leading companies dropping by double-digit rates. NTLA management will likely talk down the effects of the patent ruling, but given the new dynamics, this speculative trade has be...
Steven Bernstein, M.D. appointed to chief medical officer Susan Abu-Absi, Ph.D. promoted to chief technology & manufacturing officer 2seventy bio, Inc . (NASDAQ: TSVT) announced that Steven Bernstein, M.D. will join the company effective today and assume the ...
2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference; Fireside chat, Wednesday, February 16, 2022, at 2:20pm ET Cowen Virtual 42 nd Annual...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I a...
ABECMA generated approximately $150M U.S. revenue in 2021, equally shared by 2seventy bio and Bristol Myers Squibb; anticipate continued ABECMA growth in 2022 with $250-300M U.S. revenue bbT369 IND cleared - program tests three layers of innovation in B-NHL; achieved goal of t...
Collaboration further validates 2seventy bio’s megaTAL ™ gene editing platform with potential applicability across company’s oncology pipeline 2seventy bio is eligible to receive $40M in near-term payments, in addition to future milestone payments and ...
News, Short Squeeze, Breakout and More Instantly...
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired th...
2024-06-06 06:15:03 ET Goldman Sachs analyst issues SELL recommendation for TSVT on June 6, 2024 05:06AM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.56 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media pa...